a place fir glp.1 and eating disprders GLP-1 access problem for people with disorders Implications of GLP-1 medications for

Yang T, Wang L, Zhu M, Zhang L, Yan L

& Yang, Z

Lira was found in PA-induced Kupffer cells to reduce HF diet-induced hepatic steatosis by inhibiting NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome activation [62]

Pandya, C

[11] [12] Currently available GLP-1 receptor agonists in the United States include semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), liraglutide (Victoza, Saxenda), exenatide (Byetta, Bydureon BCise), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GLP-1/GIP receptor agonist

doi: 10.1002/cne.24779 42 BartelDLSullivanSLLavoieGSvignyJ